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Association of more negative attitude
towards commencing insulin with lower
glycosylated hemoglobin (HbA1c) level: a
survey on insulin-naïve type 2 diabetes
mellitus Chinese patients
Sau Nga Fu1* , Carlos King Ho Wong2, Weng Yee Chin2 and Wan Luk1
Abstract
Background: Delay in commencing insulin among type 2 Diabetes Mellitus (DM) patients is common. One of the
reasons is patients' psychological insulin resistance, which is particularly prevalent in Chinese patients. This study
examined the correlation between socio-demographic and clinical characteristics; and attitudes towards
commencing insulin in Chinese primary care patients.
Method: A cross-sectional survey was conducted on 303 insulin-naïve Type 2 DM patients recruited from 15
primary care clinics across Hong Kong using the Chinese Attitudes to Starting Insulin Questionnaire (Ch-ASIQ).
Subject selection criteria were patients on maximal oral anti-diabetes treatment who needed to commence insulin
therapy. Linear regression was used to identify correlations between age, sex, educational level, occupation, body
mass index, diabetes disease duration, laboratory test indicating disease control and biochemical markers including
glycosylated hemoglobin (HbA1c) level, low density lipoprotein level and estimated glomeruli filtration rate, and
presence of diabetic complications with the four sub-scales (self-image and stigmatization; factors promoting
self-efficacy; fear of pain or needles; time and family support ) and the overall Ch-ASIQ score.
Results: The most prevalent negative attitude was ‘fear of needle injections’ (70.1 %). The most common positive
attitude was ‘I can manage the skill of injecting insulin’ (67.5 %). The mean Ch-ASIQ score of 2.50 (S.D. = 0.38) was
equal to the mid-score, which signified an overall ambivalent attitude among the study population. Women scored
significantly higher in the fear of pain or needles subscale (p = 0.011) and had an overall more negative attitude
towards commencing insulin (p = 0.016). Subjects with lower HbA1c levels also had a significantly lower Ch-ASIQ
sum score (p = 0.048) indicating a more negative attitude towards commencing insulin.
Conclusion: In Chinese primary care patients with Type 2 DM, the need to commence insulin was associated with
a number of negative emotions, which lead to a lower motivation to accept treatment. Perception of need as
indicated by HbA1c level may be an important influencing factor determining a patient’s overall attitude towards
starting insulin. Fortunately, in our setting, the injection technique does not appear to be a major barrier. However,
needle fears are common, especially amongst women. Target interventions to acknowledge and help them to
overcome their fears are essential before insulin treatment is commenced.
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Background
Current guidelines recommend that insulin treatment
should be initiated as early as possible in patients with
Type 2 diabetes mellitus (DM) who fail to achieve ad-
equate glycemic control on oral drugs only, as early initi-
ation of insulin has been shown to improve outcomes
[1]. Delays in commencing insulin are commonly ob-
served in studies conducted in the United States and the
United Kingdom [2, 3], which have been shown to result
in higher risks of DM complications [4]. Previous studies
have identified that the reasons for delay are often re-
lated to psychological, cognitive and physical barriers
from the perspectives of both patients and their physi-
cians [5]. Patients’ reluctance to initiate insulin, termed
‘Psychological Insulin Resistance’ (PIR) [6] is an area of
interest to researchers because health care professionals
need to be informed on how to assist patients to over-
come their barriers. There is evidence of ethnic differ-
ences in the reasons behind the resistance to starting
insulin [7]. In Asia, and in particular Chinese patients
with DM, a higher fear of injection and a greater percep-
tion of hardship towards using insulin was observed
when compared with patients in Western settings [8, 9].
Women and patients with lower education levels have
also been identified as having greater PIR [10].
Worldwide, as the prevalence of Type 2 DM increases,
the number of patients needing to commence insulin is
foreseeably going to rise [11]. Health care professionals
will start to encounter more and more patients with
PIR, and there will be a need for more evidence-based
strategies on how to help patients overcoming their bar-
riers to commencing insulin.
The predictors and factors associated with specific key
attitudes towards insulin can inform the development of
evidence-based interventions, to help patients to overcome
their PIR and enhance acceptance to initiate insulin [12].
Therefore, this study aimed at exploring the relationship
between socio-demographics and clinical characteristics
(as indicated by their laboratory results and presence of
diabetic complications), and attitudes towards commen-
cing insulin in type 2 DM patients requiring insulin [13].
Methods
Participants
Subjects were recruited from 15 government-funded pri-
mary care general outpatient clinics (GOPCs) located in
Kowloon, New Territories and Lantau Island of Hong
Kong. Clinic nurses and doctors identified all eligible
Chinese-speaking DM patients using the computerized
laboratory result enquiry system and the drug dispensing
system from July 2011 to March 2013. Inclusion criteria
included: age between 18 and 80 years; on maximum rec-
ommended dosage of oral anti-diabetes treatment OADs
(defined by either on Gliclazide 320 mg, Gliclazide modified
release 120 mg, Glibenclamide 15 mg or metformin ≥2 g
daily or Dipeptidyl peptidase-4 inhibitors or alpha glucosi-
dase inhibitor); and the most recent HbA1c level ≥7.5 %
(58.5 mmol/mol) within past 12 months indicating insuffi-
cient glycaemic control [1, 14]. Subjects who were preg-
nant, or unable to answer a questionnaire due to mental
incapacity, or who had already commenced on insulin
were excluded.
Data collection
All eligible subjects were flagged in the computerized
appointment system before their scheduled clinic appoint-
ment. Following the medical consultation with the GOPC
doctor, the targeted subjects were approached by trained
research assistants (RAs) who explained the study, ob-
tained signed informed consent, and distributed the study
questionnaire. Participants were encouraged to self-
administer the traditional Chinese questionnaire as far as
possible. However, as a large proportion of the patients at-
tending the GOPCs are elderly and have poor literacy or
eyesight, the RAs helped to administer the questionnaires
using local Cantonese to those who were unable to
complete the questionnaire by themselves.
Questionnaires
A locally validated instrument, the 13-item Chinese Atti-
tudes to Starting Insulin Questionnaire (Ch-ASIQ) was
used to assess patients’ attitudes to starting insulin. The
psychometric properties of the Ch-ASIQ have been eval-
uated and found to have four sub-scales consisting of 3
items related to ‘Self-image and stigmatization’; 5 items
related to ‘Factors promoting self-efficacy; 3 items re-
lated to ‘Fear of pain or needles’; and 2 items related to
‘Time and family support’ (Appendix) [13]. Responses to
each item are scored using a 4-point Likert scale (Totally
disagree = 1, Disagree = 2, Agree = 3; Totally Agree = 4).
Individual scale scores are calculated by summing of the
item responses. For two of the subscales ‘Factors pro-
moting self-efficacy’ and ‘Time and family support’,
higher scores indicates more positive attitudes towards
the use of insulin. For the other two subscales ‘Self-
image and stigmatization’ and ‘Fear of pain or needles’ a
higher score indicates a more negative attitude towards
insulin initiation. The weighted sum of all four scale
scores, converting two positively coded scales to nega-
tively coded scales, calculates the Ch-ASIQ overall
score with higher scores indicating more negative atti-
tude to starting insulin. All subscale and overall
scores range from 1 to 4, with a mid-point of score
2.5. The Cronbach’s alpha coefficients for the four
factors were above 0.60 (0.62–0.80). It is the first psy-
chometric validated questionnaire on barriers to start-
ing insulin for diabetic patients in the primary care
setting [13].
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DM complications assessment
All Type 2 DM patients who attend the GOPC undergo
routine laboratory tests, retinal photo or ophthalmolo-
gist assessment and nurse-led diabetes complication
screening clinics under the Risk Factor Assessment &
Management Programme (RAMP) [15, 16] which is
conducted once every 1–2 years as part of their usual
chronic disease managed care. Plasma glycosylated
hemoglobin (HbA1c) level, estimated glomerular filtration
rate (eGFR; ml min−11.73 m−2) by Modification of Diet in
Renal Disease Formula, lipid profile (including low density
lipoprotein LDL; mmol/L), urinary albumin-to-creatinine
ratio (ACR; mg/mmol) were assessed in associated hos-
pital or Department of Health Central Laboratories.
Presence of foot ulcers and DM neuropathy (by using
10-g monofilament plus testing vibration perception
threshold) were assessed by trained GOPC nurses. Presence
of diabetic retinopathy diagnosis was confirmed either
by registered optometrist, ophthalmologist or GOPC
physicians. Presence of DM complications, physician
diagnosis of hypertension, peripheral vascular disease,
ischemic heart disease and stroke, all the biomedical
and socio-demographic data were reviewed via the Hospital
Authority’s computerized patient records.
Ethics
The Research Ethics Committee of the Kowloon West
Cluster, Hospital Authority of Hong Kong granted research
ethics approval of the research protocol.
Statistical analysis
From the power analysis with a sample size of 303 patients
recruited in this study, a 99.8 % power was achieved to de-
tect an R-square of 0.126 attributed to 13 independent
variables using an F-test with a significance level of 0.05.
Hence, the sample size retained the sufficiently high
power for regression analysis.
Descriptive statistics were calculated with median
and interquartile ranges (IQR) for continuous vari-
ables, and frequency and proportion for categorical
variables. Proportions of patients giving choices of
“Agree” or “Totally Agree” for each item of Ch-ASIQ
were calculated. Mean and standard deviation of 13 in-
dividual item scores and 4 scale scores were shown.
Linear regressions were performed to explore the asso-
ciations of scale scores and overall score of Ch-ASIQ
with patients’ socio-demographic and clinical charac-
teristics. IBM SPSS Statistics for Windows, Version
21.0 statistical software was used to conduct descrip-
tive and linear regression analyses.
Results
Of the 306 potential subjects approached, three refused to
participate (response rate =99.0 %). The socio-demographic
and clinical characteristics of the subjects are shown in
Table 1. Typical of the patient population attending
government-funded primary care clinics, these subjects
were elderly (median age 63, interquartile range (IQR) =
54–70), had lower levels of educational attainment (56.5 %
primary or below), and only one third were in full-time
employment.
The median duration of Type 2 DM was 11 years
(IQR = 7 to 16 years) and median HbA1c level was 8.3 %
(67.2 mmol/mol) [IQR = 7.9 % (62.8 mmol/mol) to 9.1 %
(76.0 mmol/mol)] indicating overall very poor level of
glycemic control. Most subjects (94.7 %) were on two
kinds of OADs (combination of metformin with another
sulphonylurea) while 1.3 % were on monotherapy and
4 % were on 3 kinds of OADs (combination of metfor-
min with sulphonylurea and dipeptidyl peptidase-4 in-
hibitors or alpha glucosidase inhibitor). Seventy-two
percent of them were either obese (54.2 %) or over-
weight (17.4 %). Most of them (81.2 %) had concomitant
hypertension, while few subjects had coexisting stroke
(4.8 %) and ischemic heart disease (1.7 %). Their LDL
level (median = 2.5 mmol/L,IQR 2.0–3.0) and estimated
glomerular filtration rate eGFR (median =88.0 ml/min/
1.73 m2, IQR 70.5–108.0) were overall clinically optimal.
The most common DM complication in this population
was retinopathy (57.5 %), followed by nephropathy
(16.8 %) and neuropathy (2.0 %).
Descriptive statistics of the 13 items and overall score
of Ch-ASIQ are shown in Table 2. Due to missing
values, 8 (2.6 %), 30 (9.9 %), 10 (3.3 %), 18 (5.9 %), and
41 (13.5 %) patients were excluded from the analysis of
scale 1, scale 2, scale 3, scale 4 and the overall Ch-ASIQ
score, respectively. Mean scores for each subscale were
calculated. Higher mean subscale scores in scale 1 (self-
image and stigmatization) and scale 3 (fear of pain or
needles) showed more negative attitudes towards insulin,
whilst higher mean subscale scores in scale 2 (factors
promoting self-efficacy) and scale 4 (Time & family sup-
port) showed more positive attitudes. The overall Ch-
ASIQ scored 2.50 (S.D. 0.38) which was the mid-point
score. It indicated overall ambivalence to starting insulin.
The highest three negative attitudes regarding starting
insulin were “I am afraid of needle injection” (70.6 %),
followed by “injecting insulin is painful” (66.9 %), and
“There is no social support available if I have to inject
insulin” (55.6 %). The highest three positive attitudes to-
wards starting insulin all belonged to scale 2: the factors
promoting self-efficacy: “I can manage the skill of injecting
insulin” (67.5 %); followed by “I can pay as close attention
to my diet as my insulin treatment required” (66.7 %); and
“insulin can help control blood glucose and prevent
complications” (63.7 %).
Results of the linear regression analysis showing the
factors and the scores of Ch-ASIQ are shown in Table 3.
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More negative attitudes to starting insulin were found in
women (p = 0.01 6). Being female accounted for 16.4 %
of variance of the negative attitude towards insulin.
While the most significant factors among women was
fear of pain or needles (p = 0.011), which accounted for
26.2 % of the variance of the negative attitude. Inter-
viewer administered subjects had lower self-efficacy
when compared with self-administered subjects. Subjects
with lower HbA1c levels had significantly higher barriers
to starting insulin. Subjects on larger number of OADs
had more factors promoting self-efficacy for insulin ther-
apy (p = 0.04) including: better up-to-date knowledge
(item#4);better social support for insulin treatment
(item#7); higherbelief that insulin can help control blood
sugar (item#5); better confidence that they can manage
the skill of injecting insulin (item#6) and diet control
(item#8). Age, education level, working status, duration
of DM, coexisting hypertension and complicated with
retinopathy showed no significant differences in the
overall scores and subscales of Ch-ASIQ.
Discussion
The study population characteristics showed that they
were representative of the type 2 DM patients attending
GOPCs in Hong Kong [17]. Despite their overall older
age 63 (IQR: 54–70) and low education level (56.5 %
attained primary education or below), more than 65 % of
them believed that they could manage theinjection skill
and diet modifications associated with insulin treatment
(item #6 & #8) (Appendix), which had been found to be
a barrier to insulin in previous studies [18]. These posi-
tive attitudes could be acknowledged and reinforced
when health care professionals tried to introduce insulin
to their patients. On the other hand, a negative self-
image and fear on insulin injection might cause much
emotional distress, which could potentially outweigh
their perceived confidence in managing the treatment.
Understanding such commonly encountered ambiva-
lent negative emotions and positive cognitions [5] is an
essential basic step to build trusting relationships with
patients. Training in proper injection techniques and
provision of a structured program of face-to-face and
telephone support are helpful strategies in initiating in-
sulin in the primary are setting [12]. Involvement of a
multidisciplinary health care team, provision of equip-
ment for injection, and home sugar monitoring appear
to be essential elements for the successful initiation of
insulin in primary care setting [19].
As with many other studies, fear of pain and needles
was an important barrier to starting insulin [9, 10] espe-
cially in women [8, 20]. Patients with a needle phobia
would typically want to avoid medical treatments involv-
ing needles [20]. This finding was consistent to patients’
avoidance of insulin injection despite their poor glycemic
Table 1 Sociodemographic and clinical charactistics of type 2
diabetic patients at baseline
Characteristics Total (N = 303)
Sociodemographic
Age (year; median, IQR) 63 (54–70)
Gender (%)
Male 136 (44.9 %)
Female 167 (55.1 %)
Education (%)
No formal education 44 (15.4 %)
Primary 117 (41.1 %)
Secondary 107 (37.5 %)
Tertiary 17 (6.0 %)
Occupation (%)
Full time work 90 (32.8 %)
Unemployed/retired 82 (29.9 %)
Housewife 99 (36.1 %)
Part time 3 (1.1 %)
Mode of Administration (%)
Self 104 (34.3 %)
Interviewer 199 (65.7 %)
Clinical
Duration of DM (year; median, IQR) 11 (7–16)
Number of DM drug (%)
On monotherapy 4 (1.3 %)
On two drug therapy 287 (94.7 %)
On three drug 12 (4.0 %)
BMI (kg/m2; median, IQR) 25.2 (22.6–27.7)
BMI cutoff
Underweight (<18.5) 5 (1.7 %)
Normal range (≥18.5–<23) 80 (26.8 %)
Overweight (≥23–<25) 52 (17.4 %)
Obese (≥25) 162 (54.2 %)
HbA1c (%; median, IQR) 8.3 (7.9–9.1)
LDL (mmol/L; median, IQR) 2.5 (2.0–3.0)
eGFR (ml/min/1.73 m2 ; median, IQR) 88.0 (70.5–108.0)
History of
Hypertension (%) 246 (81.2 %)
Nephropathy (%) 49 (16.8 %)
Footulcer (%) 4 (1.4 %)
Neuropathy (%) 6 (2.0 %)
PVD (%) 0 (0.0 %)
Retinopathy (%) 165 (57.5 %)
IHD (%) 5 (1.7 %)
Stroke (%) 14 (4.8 %)
IQR interquartile range, BMI body mass index, LDL low-density lipoprotein,
eGFR epidermal growth factor receptor
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control. Health care professionals can consider different
interventions to overcome needle phobia, such as use of
different injection devices or injection sites,[19, 21] and
specific counselling to overcome needle phobias [22].
Subjects with lower HbA1c were observed to have
greater attitudinal barriers to starting insulin. This seems to
be unique to our setting as no such association has been re-
ported in previous studies [8, 10, 23]. Patients may under-
stand their glycemic control as “better” or “acceptable”
evidenced by lower HbA1c level. This finding could pos-
sibly be explained by previous study finding that the refusal
of insulin was caused by patients did not see the necessity
for insulin and they actively seek ways to control blood
sugar within insulin [5]. Patients may perceive insulin as
the last resorts [24]. Subjects in this study had recent
HbA1c levels >7.5 %, which signified poor control yet, they
may not have perceived that their DM control was suffi-
ciently poor to require insulin. Such disagreements between
patient perceptions of glycemic control with the actual
HbA1c level may need to be addressed during patient edu-
cation process. Patient empowerment programs involving
self-awareness of treatment target and control level may be
helpful to define the best time to starting insulin [25, 26].
Subjects using more types of OADs were found to have
significantly higher scores in the subscale related to pro-
moting self-efficacy, which was a positive factor for start-
ing insulin. Adding more types of OADs may be one of
the acceptable ways to control blood sugar without insu-
lin. Yet, more types of OADs will raise the patients’ aware-
ness of poor glycemic control. They may possibly be
better mentally prepared to accept insulin therapy. Health
care professionals can target the patients on multiple
OADs for insulin education program.
There were several limitations in this study. The ques-
tionnaires were interviewer-administered in majority of
the subjects as our patient population has poor literacy
levels. It is possible that the Ch-ASIQ score may differ if
self-administered. The observed correlation might not
be applicable to other cultural or age group patients
because all subjects were Chinese in primary care out-
patient clinics and most of them were older adults. The
resulting score were asked attitude to insulin initiation
by cross sectional survey, which might not reflect actual
patient refusal behavior when physicians prescribed in-
sulin to them.
Conclusion
In summary, the most significant barriers to commence-
ment of insulin in poorly controlled Type 2 DM Chinese
primary care patients appears to be fear of pain and nee-
dles. However, most patients are aware of the clinical ef-
fectiveness of insulin and have sufficient confidence to
learn the skill of insulin injection and how to manage
their diet when taking insulin. Women and subjects with
Table 2 Mean scores of Ch-ASIQ overall, each individual item and scale, and distribution of responses to individual items
Scale/individual item Mean ± SD Agree/Totally agree (%)
Scale 1a Self image and stigmatization (n = 295) 2.44 ± 0.69
Item #1 I worry that people will know I have diabetes if I am on insulin treatment 2.36 ± 0.85 121 (40.33 %)
Item #2 Injecting insulin is embarrassing, I worry about being seen when I inject insulin 2.49 ± 0.81 147 (49.16 %)
Item #3 If I have to inject insulin, it makes me feel like a drug addict 2.45 ± 0.80 133 (44.93 %)
Scale 2b Factors promoting self-efficacy (n = 273) 2.60 ± 0.47
Item #4 I have up-to date knowledge about diabetes management 2.60 ± 0.83 189 (63.21 %)
Item #5 Insulin can help control blood glucose and prevent complications 2.65 ± 0.68 181 (63.73 %)
Item #6 I can manage the skill of injecting insulin 2.72 ± 0.75 201 (67.45 %)
Item #7 There is social support available if I have to inject insulin 2.37 ± 0.68 131 (44.41 %)
Item #8 I can pay as close attention to my diet as my insulin treatment requires. For
example, I may need to take a snack or reduce my eating amount appropriately
2.67 ± 0.66 196 (66.67 %)
Scale 3a Fear of pain or needles (n = 293) 2.76 ± 0.62
Item #9 Injecting insulin is painful 2.79 ± 0.73 200 (66.89 %)
Item #10 I am afraid of needle injections 2.91 ± 0.86 211 (70.57 %)
Item #11 I worry about needing to perform home blood sugar monitoring 2.59 ± 0.82 158 (53.02 %)
Scale 4b Time & family support (n = 285) 2.51 ± 0.62
Item #12 I can spare enough time to perform insulin injections 2.58 ± 0.71 176 (59.46 %)
Item #13 My family will support me to inject insulin 2.45 ± 0.73 133 (45.70 %)
Ch-ASIQ Overalla (n = 262) 2.50 ± 0.38
Note:
aHigher scores indicate the greater level of barriers to insulin
bHigher scores indicate the lower level of barriers to insulin
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Table 3 Factors associated with the Ch-ASIQ scale and overall scores
Scale 1a self image and
stigmatization
Scale 2b factors promoting
self-efficacy
Scale 3a fear of pain or
needles
Scale 4b time & family
support
Ch-ASIQ overalla
Factor Coeff (95 % CI) P-valuec Coeff (95 % CI) P-valuec Coeff (95 % CI) P-valuec Coeff (95 % CI) P-valuec Coeff (95 % CI) P-valuec
Sociodemographic
Age Age −0.004
(−0.016,0.008)
0.516 −0.008
(−0.016,0.001)
0.066 −0.003
(−0.014,0.008)
0.566 0.000
(−0.012,0.011)
0.945 0.003
(−0.005,0.010)
0.484
[Sex = 2] Female 0.163
(−0.056,0.381)
0.145 −0.100
(−0.256,0.055)
0.206 0.260
(0.060,0.461)
0.011 −0.052
(−0.261,0.157)
0.626 0.164
(0.031,0.297)
0.016
[Education_r = 2] Education
(No formal
education)
0.516 0.279 0.845 0.496 0.893
[Education_r = 1] • Secondary
or above
0.146
(−0.139,0.432)
0.314 0.162
(−0.041,0.365)
0.117 0.059
(−0.199,0.317)
0.654 0.148
(−0.123,0.418)
0.285 −0.039
(−0.212,0.134)
0.656
[Education_r = 0] • Primary 0.053
(−0.214,0.320)
0.696 0.096
(−0.094,0.285)
0.322 0.071
(−0.169,0.312)
0.562 0.146
(−0.106,0.398)
0.256 −0.037
(−0.199,0.125)
0.655
[Occupation_r = 3] Working Status
(Working)
0.341 0.969 0.504 0.274 0.646
[Occupation_r = 2] • Housewife −0.152
(−0.414,0.110)
0.257 0.024
(−0.161,0.208)
0.802 0.135
(−0.106,0.376)
0.272 0.149
(−0.104,0.402)
0.249 −0.045
(−0.205,0.115)
0.583
[Occupation_r = 1] • Unemployed/
retired
−0.170
(−0.416,0.076)
0.175 0.008
(−0.164,0.180)
0.925 0.100
(−0.123,0.324)
0.379 0.187
(−0.051,0.426)
0.123 −0.070
(−0.217,0.078)
0.354
• Interviewer
Administration
0.074
(−0.109,0.258)
0.427 −0.167
(−0.294, −0.040)
0.010 0.140
(−0.029,0.309)
0.105 0.063
(−0.113,0.238)
0.484 0.104
(−0.005,0.212)
0.060
Clinical
DM_Duration Duration of DM −0.012
(−0.028,0.003)
0.120 0.005
(−0.005,0.016)
0.329 0.002
(−0.012,0.016)
0.761 0.004
(−0.011,0.019)
0.594 −0.006
(−0.015,0.003)
0.208
Drug_no Number of
DM drug
−0.138
(−0.489,0.214)
0.443 0.256
(0.011,0.500)
0.040 −0.055
(−0.373,0.264)
0.735 0.003
(−0.326,0.332)
0.985 −0.166
(−0.371,0.038)
0.111
[BMI2_r = 3.00] BMI (Underweight/
Normal)
0.390 0.225 0.434 0.181 0.906
[BMI2_r = 2.00] • Obese −0.143
(−0.351,0.065)
0.178 −0.128
(−0.275,0.018)
0.086 −0.125
(−0.314,0.065)
0.197 0.135
(−0.065,0.335)
0.186 −0.016
(−0.141,0.108)
0.800
[BMI2_r = 1.00] • Overweight −0.121
(−0.395,0.153)
0.386 −0.094
(−0.285,0.097)
0.334 −0.072
(−0.328,0.183)
0.578 0.237
(−0.025,0.499)
0.076 −0.037
(−0.199,0.126)
0.659
HbA1c HbA1c (Unit in %) −0.034
(−0.110,0.042)
0.385 0.049
(−0.004,0.102)
0.071 −0.041
(−0.113,0.030)
0.255 0.037
(−0.037,0.111)
0.325 −0.046
(−0.091,0.000)
0.048
LDL LDL (Unit in
mmol/L)
−0.064
(−0.178,0.050)
0.271 0.024
(−0.053,0.101)
0.540 −0.043
(−0.148,0.061)
0.419 0.050
(−0.057,0.157)
0.358 −0.057
(−0.123,0.009)
0.092
eGFR eGFR (Unit in
ml/min/1.73 m2)
0.002
(−0.002,0.006)
0.448 0.002
(−0.001,0.005)
0.186 0.000
(−0.003,0.004)
0.828 0.001
(−0.002,0.005)
0.443 −0.001
(−0.003,0.002)
0.662
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Table 3 Factors associated with the Ch-ASIQ scale and overall scores (Continued)
History of
[HT = 1] • Hypertension 0.131
(−0.088,0.349)
0.242 0.089
(−0.066,0.243)
0.261 0.004
(−0.199,0.207)
0.971 −0.006
(−0.215,0.203)
0.955 −0.022
(−0.155,0.112)
0.751
[Nephropathy = 1] • Nephropathy 0.250
(−0.025,0.524)
0.074 0.055
(−0.133,0.242)
0.569 0.292
(0.045,0.538)
0.020 −0.060
(−0.317,0.197)
0.649 0.109
(−0.048,0.266)
0.175
[Retinopathy = 1] • Retinopathy 0.059
(−0.115,0.233)
0.509 0.055
(−0.066,0.176)
0.376 0.079
(−0.080,0.239)
0.328 0.031
(−0.134,0.196)
0.712 0.013
(−0.090,0.115)
0.810
Note:
aHigher scores indicate the greater level of barriers to insulin
bHigher scores indicate the lower level of barriers to insulin
cBold indicates the statistically significant with P-value <0.05
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lower HbA1c had more negative attitude towards start-
ing insulin. Women had higher fear of pain or needles.
Subjects on more types of OADs may be more ready to
receive new DM treatment information. To better address
conflicting attitudes towards insulin, health care pro-
fessionals can offer tailored education, which has been
shown to be beneficial to poorly controlled DM patients
to specifically address the negative attitudes identified in
this study.
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